Life science partner targets a giant market
Swiss life science enterprises lead the market globally at the cutting edge of R&D and innovation. The Swiss service provider CARBOGEN AMCIS offers drug development and commercialization services to innovative pharma and biopharma companies at all stages of drug development.
"We are dedicated to helping companies reduce the cost, risks and time associated with taking a drug to market by offering integrated services and solutions for drug substances and drug products," said Alan Fischer, CIO of CARBOGEN AMCIS.
"We are engaged in all areas of development including conjugation of small and large molecules, development and manufacture of highly potent drug substances, chromatography and drug products applying state-of-the-art containment technologies."
